Search results
Results from the WOW.Com Content Network
The unchanged drug was 96% bound to plasma proteins. The blood-level decline of the parent drug was biphasic, with the short half-life ranging from 0.4 to 0.6 hours and the terminal half-life from 3.5 to 18.4 hours (mean 8.8 hours), depending on the study population and method of determination. [62]
The elimination half-life is how long it takes for half of the drug to be eliminated by the body. "Time to peak" refers to when maximum levels of the drug in the blood occur after a given dose. "Time to peak" refers to when maximum levels of the drug in the blood occur after a given dose.
Flurazepam [2] (marketed under the brand names Dalmane and Dalmadorm) is a drug which is a benzodiazepine derivative. It possesses anxiolytic, anticonvulsant, hypnotic, sedative and skeletal muscle relaxant properties. It produces a metabolite with a long half-life, which may stay in the bloodstream for days. [3]
Somnifacient (from Latin somnus, sleep [1]), also known as sedatives or sleeping pills, is a class of medications that induces sleep. It is mainly used for treatment of insomnia . Examples of somnifacients include benzodiazepines , barbiturates and antihistamines .
Some of the symptoms that could possibly occur as a result of a withdrawal from benzodiazepines after long-term use include emotional clouding, [1] flu-like symptoms, [5] suicide, [11] nausea, headaches, dizziness, irritability, lethargy, sleep problems, memory impairment, personality changes, aggression, depression, social deterioration as ...
Flutemazepam was initially first synthesized in 1965, [1] but was not further described until a team at Stabilimenti Chimici Farmaceutici Riuniti SpA in the mid-1970s. [2] [3] It is a short-acting (9–25 hr elimination half-life) fluorinated analogue of temazepam that has powerful hypnotic, sedative, amnesiac, anxiolytic, anticonvulsant and skeletal muscle relaxant properties.
Lormetazepam, sold under the brand name Noctamid among others, is a drug which is a short to intermediate acting 3-hydroxy [3] benzodiazepine derivative and temazepam analogue. [4] It possesses hypnotic , anxiolytic , anticonvulsant , sedative , and skeletal muscle relaxant properties.
This is a list of investigational sleep drugs, or drugs for the treatment of sleep disorders that are currently under development for clinical use but are not yet approved. Chemical/generic names are listed first, with developmental code names, synonyms, and brand names in parentheses.